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Synthesis of Kurasoin B Analogs  
Kurasoin B (1), isolated in 1996 by Uchida et al, selectively inhibits 
Farnesyltransferase (FTase), an enzyme responsible for activating 
human RAS proteins (ref. 1).  When RAS proteins are mutated and 
then activated, they contribute 20 to 30 percent of all human tumors, 
including those of the pancreas, colon, small intestine, lung, prostate, 
liver, skin, and thyroid, as well as multiple myeloma and a number of 
leukemias (ref. 2).  Kurasoin B, therefore, has great potential as a 
cancer drug lead. 
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 Unfortunately, the natural abundance 
of 1 is small, and its FTase-inhibiting potency 
is only moderate (IC50 = 59 µM).  Increased 
potency might be achieved by making and 
testing analogs of 1.  Naturally, this can only 
be done through total synthesis. 
Applying Phase-Transfer Catalysis 
(PTC) to Asymmetric Alkylation 
Our group recently completed an enantioselective total synthesis of 
kurasoin B using asymmetric phase-transfer-catalyzed alkylation (ref. 
3).  This method follows the generic scheme below, in which a 
compound of type 2 is treated with a metal-hydroxide base under 
biphasic conditions, giving Z-enolate 3.  This complexes 
electrostatically with a charged, chiral phase-transfer catalyst R*4N+.  
Electrophilic attack gives products with high enantioselectivity, and 
the catalyst is released to repeat the cycle. 
Alkylating Substrate 5 
After screening multiple phase-transfer catalysts and conditions, this 
approach was applied to substrate 5 (“NAP” = 2-methylnaphthalene), 
made in three steps (73%) from 2-naphthalene methanol (ref. 4).  
Products 7 were accessed with high selectivities and yields and could 
be converted to methyl esters 8, which were deprotected (R = Bn 
only) to elucidate the absolute S configuration. 
R= %yield %ee R= %yield %ee 
90 88 Bn 85 91 
84 86 88 >99 
75 75 92 >99 
80 91 88 >99 
77 79 91 >99 
A total synthesis of kurasoin B was envisioned from product 7 ( where 
R = A), but the “NAP” group could not be removed.  Fortunately, 
exchange for a benzyl protecting group smoothly facilitated the total 
synthesis, giving synthetic kurasoin B with a 43 percent yield over 10 
steps (ref. 3) 
A 
Kurasoin B Total Synthesis 
6 
Synthesizing Kurasoin B Analogs 
Beginning with intermediate B (from the previous panel), analogs 9-11 
were made: 
1 
2 3 4 
B 
In an effort to vary the compound’s indolyl moiety, electrophile 12 was 
prepared, which is currently being used to access analogs 13-16: 
12 
13 14 15 16 
These first-generation analogs will soon be tested for their FTase inhibiting 
potency and anti-cancer pharmaceutical potential. 
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